NMR SPECTROSCOPY DATA RECOVERY METHOD AND APPARATUS
    114.
    发明公开
    NMR SPECTROSCOPY DATA RECOVERY METHOD AND APPARATUS 审中-公开
    NMR光谱数据恢复流程和设备

    公开(公告)号:EP1386180A1

    公开(公告)日:2004-02-04

    申请号:EP02719421.6

    申请日:2002-04-01

    IPC分类号: G01V3/00

    CPC分类号: G01R33/4625

    摘要: NMR spectroscopy data recovery methods and apparatus for improving the quality of an NMR spectrum are disclosed. The NMR spectrum is improved by acquiring more than the half spin-echo data signal(301) and using an iterative numerical method to reconstruct the missing data points of the corresponding full symmetrical spin-echo data signal. The method includes filtering the initial data signal to extract a low-resolution phase term (302). The low-resolution phase term is used to form a phase-constrained initial data signal, which is Fourier-transformed to obtain a reconstructed data signal (303). The reconstructed data signal is modified to include the original spin-echo signal data (304). The formation of the reconstructed spin-echo data signal and subsequent modification is iterated until convergence is obtained. The reconstructed data signal is then Fourier-transformed to form a reconstructed NMR spectrum (305).

    PULMONARY ADMINISTRATION OF THE SOLUBLE COMPLEM RECEPTOR TYPE 1 sCR1
    119.
    发明授权
    PULMONARY ADMINISTRATION OF THE SOLUBLE COMPLEM RECEPTOR TYPE 1 sCR1 失效
    可溶性补体的肺部给药的受体类型1的sCR1

    公开(公告)号:EP0682526B1

    公开(公告)日:2002-09-04

    申请号:EP94909571.5

    申请日:1994-02-08

    摘要: The present invention relates to formulations for pulmonary administration by inhalation that comprise a complement inhibitory protein, and uses thereof in the prophylactic or therapeutic treatment of diseases or disorders involving complement, especially diseases or disorders of the lung. In particular, the proteins are complement receptors of fragments thereof or soluble members of the complement receptor family that contain the conserved SCR motif and that are able to inhibit complement activity. More particularly the present invention relates to the direct treatment of certain complement related lung disorders by administering complement receptor proteins via the pulmonary route, in particular, direct delivery to the lungs of a complement receptor protein by aerosolization and subsequent inhalation. The invention also relates to use of a complement inhibitory protein to treat bronchoconstriction or anaphylaxis, or both.